University of Maryland Medical Center
Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, MD
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
DREAMM13
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Accepting patients
DREAMM12
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Not yet accepting
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Not yet accepting
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- CD3
- Phase 1
Accepting patients
P-BCMA-ALLO1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
Learn more- CAR T Cell (Allogeneic)
- BCMA
- Phase 1
- Has results
Accepting patients
iMMAGINE-1
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- Phase 2